276 related articles for article (PubMed ID: 9356680)
1. Effects of standard unfractionated and low-molecular-weight heparins on platelets of patients undergoing total hip replacement surgery.
Aulmann M; Kwasniki S; Böttiger BW; Meeder PJ
Beitr Infusionsther Transfusionsmed; 1997; 34():242-7. PubMed ID: 9356680
[TBL] [Abstract][Full Text] [Related]
2. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
3. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
4. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
[TBL] [Abstract][Full Text] [Related]
5. [Prevention of thromboembolism as a cause of thromboembolic complications. A study of the incidence of heparin-induced thrombocytopenia type II].
Ganzer D; Gutezeit A; Mayer G; Greinacher A; Eichler P
Z Orthop Ihre Grenzgeb; 1997; 135(6):543-9. PubMed ID: 9499523
[TBL] [Abstract][Full Text] [Related]
6. [Heparin-induced thrombocytopenia after elective hip joint replacement with postoperative prevention of thromboembolism with low-molecular-weight heparin].
Marx A; Huhle G; Hoffmann U; Wang LC; Schüle B; Jani L; Harenberg J
Z Orthop Ihre Grenzgeb; 1999; 137(6):536-9. PubMed ID: 10666863
[TBL] [Abstract][Full Text] [Related]
7. [Low molecular weight heparin: favorable effect profile for prevention and therapy of venous thrombosis].
Marbet GA
Ther Umsch; 1992 Dec; 49(12):843-9. PubMed ID: 1336627
[TBL] [Abstract][Full Text] [Related]
8. Suppression of intimal hyperplasia with low molecular weight heparin in a sheep model.
Ao PY; Hawthorne WJ; Coombs R; Fletcher JP
Int Angiol; 1999 Jun; 18(2):131-9. PubMed ID: 10424369
[TBL] [Abstract][Full Text] [Related]
9. [Effect of different analgesia combined with low molecular heparin on hemorheology and coagulation in patients undergoing total hip replacement].
Lou XK; Yan MJ
Zhonghua Yi Xue Za Zhi; 2010 May; 90(17):1171-6. PubMed ID: 20646562
[TBL] [Abstract][Full Text] [Related]
10. Low molecular weight heparin (Alfa LHWH) compared with unfractionated heparin in prevention of deep-vein thrombosis after hip fractures.
Pini M; Tagliaferri A; Manotti C; Lasagni F; Rinaldi E; Dettori AG
Int Angiol; 1989; 8(3):134-9. PubMed ID: 2556484
[TBL] [Abstract][Full Text] [Related]
11. [Prevention of thrombosis with unfractionated and low molecular weight heparin].
Breddin HK
Wien Med Wochenschr; 1989 Dec; 139(23):555-9. PubMed ID: 2560285
[TBL] [Abstract][Full Text] [Related]
12. [Heparin-associated thrombocytopenia caused by low-molecular-weight heparin].
Köninger J; Greinacher A; Müller-Beissenhirtz W; Strosche H
Unfallchirurg; 1995 Jan; 98(1):49-51. PubMed ID: 7886465
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of undesirable effects of low-molecular-weight heparin during prevention of thromboembolic disease in abdominal surgery patients].
Morales-Polanco MR; Sigler-Morales L; Meillón-García LA; Romero-Hernández T; Blanco-Benavides R
Gac Med Mex; 1997; 133(6):541-6. PubMed ID: 9504084
[TBL] [Abstract][Full Text] [Related]
14. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis.
Lopaciuk S; Bielska-Falda H; Noszczyk W; Bielawiec M; Witkiewicz W; Filipecki S; Michalak J; Ciesielski L; Mackiewicz Z; Czestochowska E; Zawilska K; Cencora A
Thromb Haemost; 1999 Jan; 81(1):26-31. PubMed ID: 9974369
[TBL] [Abstract][Full Text] [Related]
15. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials.
Dumaine R; Borentain M; Bertel O; Bode C; Gallo R; White HD; Collet JP; Steinhubl SR; Montalescot G
Arch Intern Med; 2007 Dec; 167(22):2423-30. PubMed ID: 18071163
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of unfractionated heparin and the low-molecular-weight heparins dalteparin and enoxaparin on spontaneous platelet aggregation and adenosine diphosphate activity in platelets during the third trimester of pregnancy.
Ajayi AA; Pharmacols FB; Cooper J; Horn EH; Rubin PC
Methods Find Exp Clin Pharmacol; 2007 Oct; 29(8):539-45. PubMed ID: 18040530
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulant effect at the time of epidural catheter removal in patients receiving twice-daily or once-daily low-molecular-weight heparin and continuous epidural analgesia after orthopedic surgery.
Douketis JD; Kinnon K; Crowther MA
Thromb Haemost; 2002 Jul; 88(1):37-40. PubMed ID: 12152674
[TBL] [Abstract][Full Text] [Related]
18. Dose response relationships of anticoagulant activities after subcutaneous administration of two low molecular weight heparins in healthy individuals.
Hellstern P; Kiehl R; von Blohn G; Köhler M; Meierhenrich U; Wenzel E
Thromb Haemost; 1986 Oct; 56(2):225-8. PubMed ID: 3810557
[TBL] [Abstract][Full Text] [Related]
19. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
Colwell C; Mouret P
Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
[TBL] [Abstract][Full Text] [Related]
20. Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement.
Marchetti M; Liberato NL; Ruperto N; Barosi G
Haematologica; 1999 Aug; 84(8):730-7. PubMed ID: 10458700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
